JP2014517313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517313A5 JP2014517313A5 JP2014514915A JP2014514915A JP2014517313A5 JP 2014517313 A5 JP2014517313 A5 JP 2014517313A5 JP 2014514915 A JP2014514915 A JP 2014514915A JP 2014514915 A JP2014514915 A JP 2014514915A JP 2014517313 A5 JP2014517313 A5 JP 2014517313A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- level
- risk
- cardiovascular disease
- measuring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 51
- 210000000130 stem cell Anatomy 0.000 claims description 44
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 32
- 230000006492 vascular dysfunction Effects 0.000 claims description 31
- 239000011859 microparticle Substances 0.000 claims description 29
- 239000012472 biological sample Substances 0.000 claims description 27
- 230000006438 vascular health Effects 0.000 claims description 11
- 230000003511 endothelial effect Effects 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 230000002250 progressing effect Effects 0.000 claims 8
- -1 CD31 Proteins 0.000 claims 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 2
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102100029761 Cadherin-5 Human genes 0.000 claims 1
- 102100037241 Endoglin Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100040120 Prominin-1 Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000001023 pro-angiogenic effect Effects 0.000 claims 1
- 238000003672 processing method Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000037998 chronic venous disease Diseases 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495955P | 2011-06-10 | 2011-06-10 | |
| US61/495,955 | 2011-06-10 | ||
| US201261650353P | 2012-05-22 | 2012-05-22 | |
| US61/650,353 | 2012-05-22 | ||
| PCT/US2012/041792 WO2012170974A1 (en) | 2011-06-10 | 2012-06-10 | System and method of cytomic vascular health profiling |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517313A JP2014517313A (ja) | 2014-07-17 |
| JP2014517313A5 true JP2014517313A5 (https=) | 2015-06-11 |
| JP6059211B2 JP6059211B2 (ja) | 2017-01-11 |
Family
ID=47296510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514915A Expired - Fee Related JP6059211B2 (ja) | 2011-06-10 | 2012-06-10 | サイトミックな血管健康プロファイリングのシステムおよび方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140357505A1 (https=) |
| EP (1) | EP2717681A4 (https=) |
| JP (1) | JP6059211B2 (https=) |
| CN (1) | CN104039134A (https=) |
| AU (1) | AU2012267489B2 (https=) |
| CA (1) | CA2838436A1 (https=) |
| WO (1) | WO2012170974A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015134791A2 (en) * | 2014-03-07 | 2015-09-11 | University Of Washington - Center For Commercialization | Non-invasive biomarker of antibody-mediated allograft rejection |
| JP2015123503A (ja) * | 2014-08-21 | 2015-07-06 | 千住金属工業株式会社 | 真空はんだ処理装置及びその制御方法 |
| AU2015360448A1 (en) * | 2014-12-10 | 2017-06-29 | Neogenomics Laboratories, Inc. | Automated flow cytometry analysis method and system |
| FR3030039B1 (fr) * | 2014-12-12 | 2018-03-16 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Caracterisation et reproduction d'un jugement d'expert pour une classification binaire |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| HRP20201651T1 (hr) * | 2015-05-07 | 2020-12-25 | Oncoimmune, Inc. | Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola |
| EP3433619A1 (en) * | 2016-03-22 | 2019-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Free functional annexin levels in plasma as a biomarker of cardiovascular risk |
| JPWO2020138351A1 (https=) * | 2018-12-28 | 2020-07-02 | ||
| CN116359488A (zh) * | 2021-12-27 | 2023-06-30 | 北京积水潭医院 | 检测血液样本中不同类型微颗粒含量的方法 |
| CN114674729B (zh) * | 2022-03-02 | 2023-11-21 | 迈克医疗电子有限公司 | 脉冲识别方法、装置、存储介质、设备及血液细胞分析仪 |
| CN120778688B (zh) * | 2025-07-09 | 2026-04-03 | 广州市微米生物科技有限公司 | 一种流式检测试剂在肿瘤疾病的出血风险等级分类产品中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233999A1 (en) * | 1999-09-06 | 2009-09-17 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| WO2004045517A2 (en) * | 2002-11-15 | 2004-06-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for the diagnosis and treatment of vascular disease |
| WO2005069003A1 (en) * | 2003-06-27 | 2005-07-28 | Oklahoma Medical Research Foundation | Methods for predicting susceptibility to cardiovascular disease |
| US20050272098A1 (en) * | 2004-04-23 | 2005-12-08 | Tramontano Anthony F | Quantitation of endothelial microparticles |
| US20060078553A1 (en) * | 2004-10-07 | 2006-04-13 | Paul Glidden | Diverse multi-unit complexes including a tRNA synthetase fragment |
| US20100203058A1 (en) * | 2009-02-11 | 2010-08-12 | Indiana University Research And Technology Corporation | Diagnostics and therapeutics based on circulating progenitor cells |
| CA2765516A1 (en) * | 2009-07-01 | 2011-01-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting cardiovascular mortality risk |
-
2012
- 2012-06-10 AU AU2012267489A patent/AU2012267489B2/en not_active Ceased
- 2012-06-10 US US14/123,920 patent/US20140357505A1/en not_active Abandoned
- 2012-06-10 CN CN201280039113.1A patent/CN104039134A/zh active Pending
- 2012-06-10 WO PCT/US2012/041792 patent/WO2012170974A1/en not_active Ceased
- 2012-06-10 JP JP2014514915A patent/JP6059211B2/ja not_active Expired - Fee Related
- 2012-06-10 EP EP12796754.5A patent/EP2717681A4/en not_active Withdrawn
- 2012-06-10 CA CA2838436A patent/CA2838436A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014517313A5 (https=) | ||
| Hättasch et al. | Galectin-3 increase in endurance athletes | |
| Salah et al. | A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score | |
| Littnerova et al. | GRACE Score among six risk scoring systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) demonstrated the best predictive value for prediction of long-term mortality in patients with ST-elevation myocardial infarction | |
| Ruparelia et al. | Inflammatory processes in cardiovascular disease: a route to targeted therapies | |
| Guazzi | Use of TAPSE/PASP ratio in pulmonary arterial hypertension: an easy shortcut in a congested road | |
| Donal et al. | Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction | |
| Capoulade et al. | Prognostic value of plasma B-type natriuretic peptide levels after exercise in patients with severe asymptomatic aortic stenosis | |
| JP2015511721A5 (https=) | ||
| JP2017527304A5 (https=) | ||
| EP2698712A3 (en) | Computer program, method, and information processing apparatus for analyzing performance of computer system | |
| JP6059211B2 (ja) | サイトミックな血管健康プロファイリングのシステムおよび方法 | |
| Tzikas et al. | GDF-15 predicts cardiovascular events in acute chest pain patients | |
| Akrawinthawong et al. | Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrast-induced nephropathy (ENCINO), a prospective study | |
| Ang et al. | The prognostic value of high sensitivity troponin T 7 weeks after an acute coronary syndrome | |
| Melin et al. | Variability in physical activity assessed with accelerometer is an independent predictor of mortality in CHF patients | |
| García-Alvarez et al. | Additional value of B-type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST-segment elevation acute coronary syndrome | |
| Fotiou et al. | Biomarkers in AL amyloidosis | |
| George et al. | Evaluation of endothelial and platelet derived microparticles in patients with acute coronary syndrome | |
| Stoica et al. | Oral anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease | |
| Shantsila et al. | Blood leukocytes in heart failure with preserved ejection fraction: impact on prognosis. | |
| IL274279B2 (en) | Predicting peptide receptor radiotherapy using a gene expression assay | |
| Zhang et al. | Combining pulse wave velocity with galectin-3 to predict mortality and cerebrovascular and cardiovascular events in hemodialysis patients | |
| Cabanas-Grandío et al. | Relative performance of three formulas to assess renal function at predicting in-hospital hemorrhagic complications in an acute coronary syndrome population. What does the new CKD-EPI formula provide? | |
| JP2015528562A5 (https=) |